



CLAIMS

1. Compounds with general formula (I)



in which



m is the number 0 or 1;

Z and Z' , which can be the same or different, are an integer ranging from 0 to 2;

Y and Y' , which can be the same or different, are $(CH_2)_{n_1}$; $(CH_2)_{n_2}-CH[NR^{VII}](CH_2)_{n_4}-NHR^I$; $-(CH_2)_{n_3}$; $CH_2-CH[CH_2-CH_2]_2-$ or $(CH_2)_{n_2}-N[(CH_2)_{n_4}-NHR^{IV}](CH_2)_{n_3}$;

Y' is selected from the group consisting of H; cycloalkyl C_3-C_7 ; $(CH_2)_{n_5}-N[CH_2-CH_2]_2N-(CH_2)_{n_6}-NHR^V$; $(CH_2)_{n_7}-CH[CH_2-CH_2]_2NR^V$;

X is O, or is a simple bond;

$n-n_8$, which can be the same or different, are an integer ranging from 0 to 5;

R^I , R^{II} , R^{III} , R^{IV} , and R^V , which can be the same or different, are a protective group for the nitrogen to which they are bound; CO_2R^{VI} ; CO_2CH_2Ar ; $CO_2(9\text{-fluorenylmethyl})$; $(CH_2)_{n_5}-NHCO_2R^{VI}$; CH_2Ar ; $COAr$; $(CH_2)_{n_5}-NHCO_2CH_2Ar$; $(CH_2)_{n_5}-NHCO_2(9\text{-fluorenylmethyl})$.

R^{VI} is a straight or branched (C_1 - C_8) alkyl;

R^{VII} is H or R^I - R^V ;

Ar is a C_6 - C_{12} aromatic residue, such as phenyl, optionally substituted with one or more groups selected from: halogen, hydroxy, C_1 - C_5 alkyl, C_1 - C_5 alkoxy, phenyl, cyano, nitro, $-NR^{VIII}R^{IX}$, where R^{VIII} and R^{IX} , which can be the same or different, are hydrogen, straight or branched (C_1 - C_5) alkyl, or Ar is a heterocyclic group, said heterocyclic group containing at least one heteroatom selected from a nitrogen atom, optionally substituted with a (C_1 - C_5) alkyl group, and/or oxygen and/or sulphur; said heterocycle can be substituted with one or more groups selected from halogen, hydroxy, C_1 - C_5 alkyl, C_1 - C_5 alkoxy, phenyl, cyano, nitro, $-NR^{VIII}R^{IX}$, where R^{VIII} and R^{IX} , which can be the same or different, are hydrogen, straight or branched (C_1 - C_5) alkyl, the N_1 -oxides, racemic mixtures, their individual enantiomers, their individual diastereoisomers, the *E* and *Z* forms, their mixtures, and pharmaceutically acceptable salts.

2. Compounds according to claim 1, in which the protective groups are bulky groups of a lipophilic nature.

3. Compounds according to claim 1, in which the protective groups are selected from the group consisting of: CO_2R^{VI} ; CO_2CH_2Ar ; CO_2 -(9-fluorenylmethyl); $(CH_2)_{n5}$ - $NHCO_2R^{VI}$; $(CH_2)_{n5}$ - $NHCO_2CH_2Ar$; $(CH_2)_{n5}$ - $NHCO_2$ -(9-fluorenylmethyl), in which R^{VI} is as defined above.

4. Compounds according to claim 3, in which the protective groups are selected from the group consisting of tert-butoxycarbonyl; benzyloxycarbonyl; 9-fluorenylmethyloxycarbonyl.

5. Compounds according to any of claims 1-4, in which m is 0.

6. Compounds according to claim 5, selected from the group consisting of:

- tert-butylester of 20S-(4-{{[3-(7-camptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino}-butyl)-(3-tert-butoxycarbonylamino)propyl)-carbamic acid;
- tert-butylester of 20S-(4-{{[3-(7-camptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino}-butyl)-carbamic acid;
- tert-butylester of 20S-[3-(7-camptothecinylidene-amino)-butyl]-carbamic acid;
- 20S-7-[3-(N-tert-butoxycarbonylamino)propoxyimino-methyl]-camptothecin.

7. Compounds according to any of claims 1-4, in which m is 1.

8. Compounds according to claim 7, selected from the group consisting of:

- tert-butylester of 20RS-(4-{{[3-(7-homocamptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino}-butyl)-(3-tert-butoxycarbonylamino)propyl)-carbamic acid;
- tert-butylester of 20RS-(4-{{[3-(7-homocamptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino}-butyl)-carbamic acid;
- tert-butylester of 20RS-[3-(7-homocamptothecinylidene-amino)-butyl]-carbamic acid;
- 20R,S-7-[3-(N-tert-butoxycarbonylamino)propoxyimino-methyl]-homocamptothecin

9. Pharmaceutical composition containing at least one compound according to claims 1-8 as the active ingredient in admixture with at least one pharmaceutically acceptable vehicle and/or excipient.

10. Use of compounds according to claims 1-8 as medicaments.

11. Use of compounds according to claims 1-8 for the preparation of a medicament with topoisomerase 1 inhibiting activity.

12. Use according to claim 11 for the preparation of a medicament with anticancer activity.

13. Use according to claim 11 for the preparation of a medicament with antiparasite activity.

14. Use according to claim 11 for the preparation of a medicament with antiviral activity.